AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients

AstraZeneca Plc AZN reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in non-small cell lung cancer (NSCLC) without actionable genomic alterations.
Datopotamab deruxtecan is jointly developed by Daiichi Sankyo DSKNY and AstraZeneca.
The interim analysis demonstrated an overall response rate in the overall population of 37% in patients receiving datopotamab deruxtecan plus Merck & Co Inc's Keytruda (pembrolizumab) (doublet therapy).
The data showed an ORR of 41% in patients receiving datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy (triplet therapy).
A disease control rate (DCR) of 84% was seen with doublet and triplet combination therapy.
In previously untreated patients, ORRs of 62% (on doublet therapy) and 50% (on triplet therapy) were observed.
Eight partial responses (PRs) were seen in patients receiving doublet therapy, and 10 PRs (three pending confirmation) were seen in patients receiving triplet therapy.
A DCR of 100% was observed with doublet therapy and 90% with triplet therapy.
Price Action: AZN shares are up 0.81% at $65.65 during the premarket session on the last check Tuesday.